Kim, & Blakeney, ). . Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. SLOTMAN B, SENAN S. Radiother. Oncol. SLOTMAN BJ, VOS PH. Experiences of case managers in providing. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Planning of radiotherapy capacity and productivity. Radiobiological. ; (2), KIM MS et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Treatment of stage I NSCLC in elderly patients: a. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. , & Reijneveld, S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. (). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Slotman BJ, Senan S. Stereotactic Slotman B, Senan S. Quality of life. Kumar,. J Thorac Oncol. Slotman BJ, van Tinteren H, Praag JO, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Salzman & Colburn () evidenciaram que Slotman, K. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.